Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
1.
Physiol Behav ; 179: 411-421, 2017 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-28716609

RESUMEN

Alcohol use disorder (AUD) negatively affects millions of people every year in the United States, and effective treatments for AUD are still needed. The neuropeptide oxytocin has shown promise for reducing alcohol drinking in mice and rats. Because oxytocin also plays a key role in complex prosocial behaviors like bonding and attachment, we tested the effect of oxytocin on alcohol drinking in prairie voles, a species that both consumes high amounts of alcohol and forms oxytocin dependent social bonds in a manner similar to humans. Oxytocin treatment (1.0, 3.0, and 10.0mg/kg, i.p.) reduced alcohol consumption in male and female prairie voles in animals that had access to 15% ethanol vs water every other day for 12 alcohol drinking sessions. In animals with continuous access to 15% alcohol and water, oxytocin (3.0mg/kg) reduced alcohol consumption only in the first hour of access after treatment, with no significant effects on consumption over the 24-hr period. In an open field locomotor test, oxytocin (1.0, 3.0, and 10.0mg/kg, i.p.) did not affect overall locomotor activity; however, ethanol (2g/kg, i.p.) increased locomotor activity in males and females, and produced anxiolytic effects (increased time in the center of an open field) in females only. Because prairie voles have been shown to match the alcohol consumption of their cage mate, we evaluated the relationship between cage mates' alcohol drinking. There was an overall pattern of social facilitation (consumption by one cage mate predicted consumption by the other cage mate); however, we found significant individual differences across cages in which many cages did not show significant matching, and, in some cases one cage mate's consumption negatively predicted the other cage mate's consumption. Overall, our data provide support for the potential of oxytocin as a treatment to reduce alcohol consumption.


Asunto(s)
Disuasivos de Alcohol/farmacología , Consumo de Bebidas Alcohólicas/tratamiento farmacológico , Oxitocina/farmacología , Análisis de Varianza , Animales , Ansiolíticos/farmacología , Ansiedad/tratamiento farmacológico , Arvicolinae , Depresores del Sistema Nervioso Central/administración & dosificación , Relación Dosis-Respuesta a Droga , Etanol/administración & dosificación , Femenino , Modelos Lineales , Masculino , Actividad Motora/efectos de los fármacos , Factores Sexuales , Conducta Social , Factores de Tiempo
2.
Crit Care ; 21(1): 108, 2017 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-28511660

RESUMEN

BACKGROUND: Simvastatin therapy for patients with acute respiratory distress syndrome (ARDS) has been shown to be safe and associated with minimal adverse effects, but it does not improve clinical outcomes. The aim of this research was to report on mortality and cost-effectiveness of simvastatin in patients with ARDS at 12 months. METHODS: This was a cost-utility analysis alongside a multicentre, double-blind, randomised controlled trial carried out in the UK and Ireland. Five hundred and forty intubated and mechanically ventilated patients with ARDS were randomly assigned (1:1) to receive once-daily simvastatin (at a dose of 80 mg) or identical placebo tablets enterally for up to 28 days. RESULTS: Mortality was lower in the simvastatin group (31.8%, 95% confidence interval (CI) 26.1-37.5) compared to the placebo group (37.3%, 95% CI 31.6-43.0) at 12 months, although this was not significant. Simvastatin was associated with statistically significant quality-adjusted life year (QALY) gain (incremental QALYs 0.064, 95% CI 0.002-0.127) compared to placebo. Simvastatin was also less costly (incremental total costs -£3601, 95% CI -8061 to 859). At a willingness-to-pay threshold of £20,000 per QALY, the probability of simvastatin being cost-effective was 99%. Sensitivity analyses indicated that the results were robust to changes in methodological assumptions with the probability of cost-effectiveness never dropping below 90%. CONCLUSION: Simvastatin was found to be cost-effective for the treatment of ARDS, being associated with both a significant QALY gain and a cost saving. There was no significant reduction in mortality at 12 months, TRIAL REGISTRATION: ISRCTN, 88244364. Registered 26 November 2010.


Asunto(s)
Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Simvastatina/efectos adversos , Tiempo , Adulto , Anciano , Análisis Costo-Beneficio , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Años de Vida Ajustados por Calidad de Vida , Síndrome de Dificultad Respiratoria/economía , Simvastatina/economía , Simvastatina/uso terapéutico , Medicina Estatal/estadística & datos numéricos
3.
J Clin Transl Sci ; 1(1): 45-52, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28480055

RESUMEN

INTRODUCTION: A pilot study by 6 Clinical and Translational Science Awards (CTSAs) explored how bibliometrics can be used to assess research influence. METHODS: Evaluators from 6 institutions shared data on publications (4202 total) they supported, and conducted a combined analysis with state-of-the-art tools. This paper presents selected results based on the tools from 2 widely used vendors for bibliometrics: Thomson Reuters and Elsevier. RESULTS: Both vendors located a high percentage of publications within their proprietary databases (>90%) and provided similar but not equivalent bibliometrics for estimating productivity (number of publications) and influence (citation rates, percentage of papers in the top 10% of citations, observed citations relative to expected citations). A recently available bibliometric from the National Institutes of Health Office of Portfolio Analysis, examined after the initial analysis, showed tremendous potential for use in the CTSA context. CONCLUSION: Despite challenges in making cross-CTSA comparisons, bibliometrics can enhance our understanding of the value of CTSA-supported clinical and translational research.

4.
Thorax ; 72(11): 971-980, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28082531

RESUMEN

RATIONALE: Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin's antiplatelet and immunomodulatory effects may be beneficial in ARDS. OBJECTIVE: To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS. METHODS: Healthy volunteers were randomised to receive placebo or aspirin 75  or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 µg of LPS. The primary outcome measure was BAL IL-8. Secondary outcome measures included markers of alveolar inflammation (BAL neutrophils, cytokines, neutrophil proteases), alveolar epithelial cell injury, systemic inflammation (neutrophils and plasma C-reactive protein (CRP)) and platelet activation (thromboxane B2, TXB2). Human lungs, perfused and ventilated ex vivo (EVLP) were randomised to placebo or 24 mg aspirin and injured with LPS. BAL was carried out 4 hours later. Inflammation was assessed by BAL differential cell counts and histological changes. RESULTS: In the healthy volunteer (n=33) model, data for the aspirin groups were combined. Aspirin did not reduce BAL IL-8. However, aspirin reduced pulmonary neutrophilia and tissue damaging neutrophil proteases (Matrix Metalloproteinase (MMP)-8/-9), reduced BAL concentrations of tumour necrosis factor α and reduced systemic and pulmonary TXB2. There was no difference between high-dose and low-dose aspirin. In the EVLP model, aspirin reduced BAL neutrophilia and alveolar injury as measured by histological damage. CONCLUSIONS: These are the first prospective human data indicating that aspirin inhibits pulmonary neutrophilic inflammation, at both low and high doses. Further clinical studies are indicated to assess the role of aspirin in the prevention and treatment of ARDS. TRIAL REGISTRATION NUMBER: NCT01659307 Results.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Aspirina/uso terapéutico , Lipopolisacáridos/administración & dosificación , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Adulto , Biomarcadores/metabolismo , Lavado Broncoalveolar , Proteína C-Reactiva/inmunología , Citocinas/inmunología , Método Doble Ciego , Femenino , Humanos , Inflamación/tratamiento farmacológico , Inhalación , Interleucina-8/inmunología , Masculino , Neutrófilos/inmunología , Estudios Prospectivos , Síndrome de Dificultad Respiratoria/diagnóstico , Síndrome de Dificultad Respiratoria/inmunología , Resultado del Tratamiento , Voluntarios
5.
Eur Respir J ; 38(4): 959-70, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21565917

RESUMEN

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) comprise a spectrum of acute inflammatory pulmonary oedema resulting in refractory hypoxaemia in the absence of an underlying cardiogenic cause. There are multiple pulmonary and extrapulmonary causes and ALI/ARDS patients are a clinically heterogeneous group with associated high morbidity and mortality. Inflammatory injury to the alveolar epithelial and endothelial capillary membrane is a central event in the pathogenesis of ALI/ARDS, and involves degradation of the basement membrane. Matrix metalloproteinases (MMPs) have been implicated in a wide variety of pulmonary pathologies and are capable of degrading all components of the extracellular matrix including the basement membrane and key non-matrix mediators of lung injury such as chemokines and cell surface receptors. While many studies implicate MMPs in the injurious process, there are significant gaps in our knowledge of the role of specific proteases at different phases of injury and repair. This article examines the role of MMPs in injury and repair of the alveolar epithelial-endothelial capillary barrier and discusses the potential for MMP modulation in the prevention and treatment of ALI. The need for further mechanistic and in vivo studies to inform appropriate subsequent clinical trials of MMP modulation will be highlighted.


Asunto(s)
Lesión Pulmonar Aguda/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Regeneración/fisiología , Síndrome de Dificultad Respiratoria/metabolismo , Lesión Pulmonar Aguda/fisiopatología , Matriz Extracelular/metabolismo , Humanos , Síndrome de Dificultad Respiratoria/fisiopatología
7.
Eur Respir J ; 33(1): 134-41, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18715875

RESUMEN

Tuberculosis (TB) pleural disease is complicated by extensive tissue destruction. Matrix metalloproteinase (MMP)-1 and -9 are implicated in immunopathology of pulmonary and central nervous system TB. There are few data on MMP activity in TB pleurisy. The present study investigated MMP-1, -2 and -9 and their specific inhibitors (tissue inhibitor of metalloproteinase (TIMP)-1 and -2) in tuberculous effusions, and correlated these with clinical and histopathological features. Clinical data, routine blood tests, and pleural fluid/biopsy material were obtained from 89 patients presenting with pleural effusions in a TB-endemic area. MMP-1, -2 and -9 were measured by zymography or western blot, and TIMP-1 and -2 by ELISA. Pleural biopsies were examined microscopically, cultured for acid-alcohol fast bacilli and immunostained for MMP-9. Tuberculous pleural effusions contained the highest concentrations of MMP-9 compared with malignant effusions or heart failure transudates. MMP-9 concentrations were highest in effusions from patients with granulomatous biopsies: median (interquartile range) 108 (61-218) pg x mL(-1) versus 43 (12-83) pg x mL(-1) in those with nongranulomatous pleural biopsies. MMP-1 and -2 were not upregulated in tuberculous pleural fluid. The ratio of MMP-9:TIMP-1 was significantly higher in TB effusions. Tuberculous pleurisy is characterised by a specific pattern of matrix metalloproteinase-9 upregulation, correlating with the presence of granulomas and suggesting a specific role for matrix metalloproteinase-9 in inflammatory responses in tuberculous pleural disease.


Asunto(s)
Granuloma del Sistema Respiratorio/etiología , Metaloproteinasa 9 de la Matriz/metabolismo , Tuberculosis Pleural/enzimología , Tuberculosis Pleural/patología , Adulto , Anciano , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Granuloma del Sistema Respiratorio/enzimología , Granuloma del Sistema Respiratorio/patología , Humanos , Masculino , Metaloproteinasa 1 de la Matriz/metabolismo , Persona de Mediana Edad , Derrame Pleural/enzimología , Derrame Pleural/etiología , Derrame Pleural/patología , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Inhibidor Tisular de Metaloproteinasa-2/metabolismo , Tuberculosis Pleural/complicaciones
8.
Reproduction ; 131(4): 805-16, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16595731

RESUMEN

We studied sequelae of prenatal plus infantile exposure of male rabbits to vinclozolin, because it is ingested by women and children. Female Dutch-Belted rabbits (7-10/group) were treated daily per orum from gestation day 15 through post-natal week 4 to provide 0, 7.2, or 72 mg vinclozolin/kg dam's body weight/day. Vinclozolin had no effect on maintenance of pregnancy, growth of pups, age at testicular descent or weight of organs. Concentrations of serum LH or testosterone at 6, 12, or 24 weeks of age were unaffected. However, FSH was lower (P < 0.05) in both vinclozolin groups at all three ages. Following injection of GnRH at 12 or 24 weeks, the increase in FSH was less (P < 0.05) in both vinclozolin groups, as was testosterone at 12 weeks of age. After full sexual maturity, 2 of 7 low dose rabbits were uninterested in female or male teasers and never achieved erection or ejaculation. Overall, rates of ejaculation failure were: control 0% (0/48), low dose 29% (12/42), and high dose 5% (3/60). Daily sperm production per gram of testis and total number of sperm per ejaculate in both vinclozolin groups were similar (P > 0.1) to controls. However, semen from vinclozolin rabbits contained over two times more (P < 0.05) morphologically abnormal spermatozoa, mostly nuclear and acrosomal defects, than semen from controls. Seminiferous tubules with degenerative changes were more frequent (P < 0.05) in vinclozolin rabbits than in controls. Lesions included syncytia of spherical spermatids and desquamation of germ cells. Hence, developmental exposure to vinclozolin caused presumably permanent changes in copulatory ability, secretion of FSH, and spermiogenesis.


Asunto(s)
Contaminación Ambiental/efectos adversos , Fungicidas Industriales/toxicidad , Exposición Materna , Oxazoles/toxicidad , Disfunciones Sexuales Fisiológicas/inducido químicamente , Espermatogénesis/efectos de los fármacos , Animales , Animales Recién Nacidos , Femenino , Hormona Folículo Estimulante/metabolismo , Masculino , Modelos Animales , Conejos , Túbulos Seminíferos/efectos de los fármacos , Túbulos Seminíferos/patología , Espermatozoides/efectos de los fármacos , Espermatozoides/patología , Testosterona/sangre
9.
Clin Exp Immunol ; 142(1): 12-20, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16178851

RESUMEN

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that perform multiple roles in the normal immune response to infection. MMPs facilitate leucocyte recruitment, cytokine and chemokine processing, defensin activation and matrix remodelling. However, excess MMP activity following infection may lead to immunopathology that causes host morbidity or mortality and favours pathogen dissemination or persistence. Here, we review the normal functions of MMPs in immunity and then discuss viral and bacterial infections where excess MMP activity has been implicated in pathology, specifically examining HIV, HTLV-1, hepatitis B, endotoxin shock, Helicobacter pylori and Mycobacterium tuberculosis. Tissue destruction may be exacerbated further by bacterial-derived enzymes which activate the host pro-MMPs. Finally, the potential for therapeutic targeting of excess MMP activity in infection is considered.


Asunto(s)
Infecciones Bacterianas/inmunología , Metaloproteinasas de la Matriz/inmunología , Virosis/inmunología , Bacterias/enzimología , Infecciones por VIH/inmunología , Infecciones por HTLV-I/inmunología , Infecciones por Helicobacter/inmunología , Helicobacter pylori/inmunología , Hepatitis B/inmunología , Humanos , Inmunidad/inmunología , Metaloproteinasas de la Matriz/metabolismo , Infecciones por Mycobacterium/inmunología , Péptido Hidrolasas/metabolismo
10.
Mol Genet Genomics ; 271(5): 603-15, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15133655

RESUMEN

The Saccharomyces cerevisiase protein phosphatase Fcp1 has been implicated in the regulation of transcription by RNA polymerase II, and is encoded by the essential gene FCP1. A screen was carried out for multicopy suppressors of the temperature-sensitive phenotype of two phosphatase mutants, fcp1-2 and fcp1-4. Only the wild-type FCP1 was found to suppress (complement) the fcp1-4 mutation. For fcp1-2 three second-site suppressors were identified. One contained the ORF for ZDS1. The remaining two suppressors mapped to the centromere regions of chromosomes I and V. Suppression due to centromere DNA was found to be more dependent on the CDEIII region than on other regions of the centromere. The presence of a suppressor centromere affected the level of Fcp1 protein and the overall phosphorylation state of RNA polymerase II (RNAPII) in fcp1-2 cells, but not wild-type cells, grown at both permissive and non-permissive temperatures. In addition, genetic interactions were identified between this FCP1 mutant and the genes SKP1, CEP3 and CBF1, which code for centromere binding proteins. The mechanism of suppression and regulation of Fcp1-2 protein activity by centromeric DNA is discussed.


Asunto(s)
Centrómero/genética , Fosfoproteínas Fosfatasas/genética , Proteínas de Saccharomyces cerevisiae/genética , Secuencia de Bases , Inestabilidad Cromosómica , ADN de Hongos , Fosforilación , ARN Polimerasa II/metabolismo , Saccharomyces cerevisiae , Supresión Genética , Temperatura
11.
Toxicol Sci ; 80(1): 83-91, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15141106

RESUMEN

To determine if dibromoacetic acid (DBA) affects ovarian folliculogenesis, four groups of female Dutch-belted rabbits were exposed daily to 0, 1, 5, or 50 mg DBA/kg body weight in drinking water beginning in utero from gestation day 15 throughout life. Functionality of the endocrine axis was assessed by measuring serum concentrations of gonadotropins following an im injection of 10 microg GnRH at 12 (prepubertal; n = 6/dose group) and 24 (postpubertal; n = 10/dose group) weeks of age. A day after GnRH challenge, number of ovulation sites and ovarian weights were determined at necropsy. Left ovaries were processed for histopathology, serially sectioned at 6 microm, and every twelfth section stained with hematoxylin and eosin was evaluated. All healthy follicles were categorized as primordial, primary, small preantral, large preantral, or small antral follicles. The area of each section evaluated was measured and the number of follicles in each category expressed per mm2 unit area. In prepubertal animals, DBA caused a reduction in number of primordial follicles (p < 0.05) and total healthy follicles (p < 0.05) at 50 mg/kg dose level. In adult animals, there were fewer primordial follicles in both the 5 (p < 0.01) and 50 (p = 0.1) mg/kg dose groups. No profound changes in gonadotropin profiles were observed. Although chronic exposure to DBA did not appear to have an effect on late follicular development or ovulation, DBA did reduce the population of primordial follicles. The long-term health consequences of diminished primordial follicles are unknown, but it is very likely that reproductive senescence would occur earlier.


Asunto(s)
Acetatos/toxicidad , Exposición Materna/efectos adversos , Oogénesis/efectos de los fármacos , Folículo Ovárico/efectos de los fármacos , Acetatos/administración & dosificación , Animales , Relación Dosis-Respuesta a Droga , Femenino , Hormona Folículo Estimulante/sangre , Lactancia , Hormona Luteinizante/sangre , Tamaño de los Órganos/efectos de los fármacos , Folículo Ovárico/crecimiento & desarrollo , Ovario/anatomía & histología , Ovario/efectos de los fármacos , Embarazo , Conejos , Factores de Tiempo , Purificación del Agua
12.
Am J Obstet Gynecol ; 184(3): 476-82, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11228506

RESUMEN

OBJECTIVE: Pregnancy alters baroreflex control of heart rate in conscious rabbits, but the mechanism for this action is unknown. This study tested the hypothesis that endogenous angiotensin II is the mediator. STUDY DESIGN: To test this hypothesis the baroreflex relationship between arterial pressure and heart rate in conscious rabbits was determined before and after administration of the angiotensin II AT1 receptor antagonist losartan (n = 7) before pregnancy and at the end of gestation. RESULTS: Pregnancy decreased mean arterial pressure, increased heart rate, and modified the reflex by shifting the mean arterial pressure-heart rate relationship to a lower pressure level, by increasing minimum heart rate, and by decreasing baroreflex gain (P < .05). Before pregnancy, losartan decreased baroreflex gain but had no other effect on reflex function. In contrast, during late gestation losartan further decreased mean arterial pressure, further decreased reflex gain, decreased maximum heart rate, and shifted the curve to a lower mean arterial pressure level (P < .05). CONCLUSION: These results suggest that in conscious rabbits during pregnancy endogenous angiotensin II contributes to hypotension-induced tachycardia but does not decrease reflex gain or elevate minimum heart rate.


Asunto(s)
Angiotensina II/fisiología , Barorreflejo/fisiología , Preñez/fisiología , Antagonistas de Receptores de Angiotensina , Animales , Antihipertensivos/farmacología , Barorreflejo/efectos de los fármacos , Presión Sanguínea , Femenino , Viabilidad Fetal/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Tamaño de la Camada , Modelos Logísticos , Losartán/farmacología , Nitroprusiato/farmacología , Fenilefrina/farmacología , Embarazo , Conejos , Receptor de Angiotensina Tipo 1 , Receptor de Angiotensina Tipo 2 , Vasoconstrictores/farmacología
14.
Physiol Genomics ; 4(1): 75-81, 2000 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-11074016

RESUMEN

A reporter construct was assembled with 4-kb of renin 5'-flanking sequence fused to humanized green fluorescent protein (GFP) cDNA. Transgenic mice carrying this construct were produced and assayed for GFP expression. In the adult, expression was detected in juxtaglomerular (JG) cells of the kidney and granular convoluted tubular cells of the submandibular gland. Furthermore, treatment of mice with captopril induced GFP expression in renal vascular smooth muscle cells. During embryogenesis, GFP expression was first detected at embryonic day E13 in the adrenal gland and Wolffian duct. Expression was also seen in the developing renal vasculature as early as E14 and remained detectable through birth. Renal GFP expression became restricted to JG cells in adults. Fetal adrenal and gonadal arteries also expressed GFP. In the placenta, GFP was observed in giant cell trophoblasts, consistent with reports of renin expression in chorionic cells of both humans and mice. We conclude that 4 kb of renin 5' flank is sufficient to direct multiple known renin expression patterns. Furthermore, the renin-GFP construct characterized here will provide a useful vital reporter for renin expression.


Asunto(s)
Envejecimiento/genética , Embrión de Mamíferos/química , Embrión de Mamíferos/metabolismo , Regulación de la Expresión Génica , Proteínas Luminiscentes/genética , Renina/genética , Transgenes , Animales , Femenino , Técnicas de Transferencia de Gen , Proteínas Fluorescentes Verdes , Humanos , Riñón/irrigación sanguínea , Riñón/química , Riñón/metabolismo , Proteínas Luminiscentes/biosíntesis , Masculino , Ratones , Ratones Transgénicos , Placenta/química , Placenta/metabolismo , Embarazo , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , Renina/biosíntesis , Glándula Submandibular/química , Glándula Submandibular/metabolismo , Sistema Urogenital/química , Sistema Urogenital/metabolismo
15.
J Biol Chem ; 275(47): 36541-9, 2000 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-10940308

RESUMEN

Many proteins involved in eukaryotic transcription are similar in function and in sequence between organisms. Despite the sequence similarities, there are many factors that do not function across species. For example, transcript elongation factor TFIIS is highly conserved among eukaryotes, and yet the TFIIS protein from Saccharomyces cerevisiae cannot function with mammalian RNA polymerase II and vice versa. To determine the reason for this species specificity, chimeras were constructed linking three structurally independent regions of the TFIIS proteins from yeast and human cells. Two independently folding domains, II and III, have been examined previously using NMR (). Yeast domain II alone is able to bind yeast RNA polymerase II with the same affinity as the full-length TFIIS protein, and this domain was expected to confer the species selectivity. Domain III has previously been shown to be readily exchanged between mammalian and yeast factors. However, the results presented here indicate that domain II is insufficient to confer species selectivity, and a primary determinant lies in a 30-amino acid highly conserved linker region connecting domain II with domain III. These 30 amino acids may physically orient domains II and III to support functional interactions between TFIIS and RNA polymerase II.


Asunto(s)
Factores Generales de Transcripción , Factores de Transcripción/fisiología , Factores de Elongación Transcripcional , Secuencia de Aminoácidos , Secuencia Conservada , Células HeLa , Humanos , Datos de Secuencia Molecular , Conformación Proteica , ARN Polimerasa II/metabolismo , Proteínas Recombinantes de Fusión/química , Saccharomyces cerevisiae , Especificidad de la Especie , Relación Estructura-Actividad , Factores de Transcripción/genética
16.
Mol Cell Biol ; 20(16): 5960-73, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10913179

RESUMEN

The eukaryotic transcript elongation factor TFIIS enables RNA polymerase II to read through blocks to elongation in vitro and interacts genetically with a variety of components of the transcription machinery in vivo. In Saccharomyces cerevisiae, the gene encoding TFIIS (PPR2) is not essential, and disruption strains exhibit only mild phenotypes and an increased sensitivity to 6-azauracil. The nonessential nature of TFIIS encouraged the use of a synthetic lethal screen to elucidate the in vivo roles of TFIIS as well as provide more information on other factors involved in the regulation of transcript elongation. Several genes were identified that are necessary for either cell survival or robust growth when the gene encoding TFIIS has been disrupted. These include UBP3, KEX2, STT4, and SWI2/SNF2. SWI1 and SNF5 disruptions were also synthetically lethal with ppr2Delta, suggesting that the reduced ability to remodel chromatin confers the synthetic phenotype. The synthetic phenotypes show marked osmosensitivity and cytoskeletal defects, including a terminal hyperelongated bud phenotype with the Swi-Snf complex. These results suggest that genes important in osmoregulation, cell membrane synthesis and integrity, and cell division may require the Swi-Snf complex and TFIIS for efficient transcription. The detection of these genetic interactions provides another functional link between the Swi-Snf complex and the elongation machinery.


Asunto(s)
Cromatina/genética , Proteínas de Unión al ADN/genética , Proteínas Nucleares , Factores Generales de Transcripción , Factores de Transcripción/genética , Factores de Elongación Transcripcional , Adenosina Trifosfatasas , Proteínas Cromosómicas no Histona , Proteínas Fúngicas/genética , Regulación Fúngica de la Expresión Génica , Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae , Activación Transcripcional
17.
Am J Physiol ; 277(3): R675-81, 1999 09.
Artículo en Inglés | MEDLINE | ID: mdl-10484483

RESUMEN

Late pregnant (P) conscious rabbits are less able to maintain arterial pressure during hemorrhage than nonpregnant (NP) animals. This study tested the hypothesis that the difference is due in part to less reflex vasoconstriction when the rabbits are P. Rabbits (n = 14) were instrumented with arterial and venous catheters as well as ultrasonic flow probes around the superior mesenteric, renal, and/or terminal aortic arteries. Pregnancy increased (P < 0.05) blood volume [235 +/- 5 (P) vs. 171 +/- 3 (NP) ml], terminal aortic conductance [1.88 +/- 0.11 (P) vs. 0.98 +/- 0.06 (NP) ml. min(-1). mmHg(-1)], mesenteric conductance [1.20 +/- 0.19 (P) vs. 0.80 +/- 0. 05 (NP) ml. min(-1). mmHg(-1)], and heart rate [191 +/- 4 (P) vs. 162 +/- 3 (NP) beats/min] and decreased arterial pressure [59 +/- 1 (P) vs. 67 +/- 2 (NP) mmHg; P < 0.05]. Renal conductance was unaltered. The rabbits were bled in both the NP and P states at 2% of the initial blood volume per minute until arterial pressure fell below 45 mmHg. Arterial pressure fell with less blood loss in P rabbits [28 +/- 2% (P) vs. 39 +/- 2% (NP) of initial blood volume; P < 0.001]. Terminal aortic conductance decreased (P < 0.001) before the pressure fall in both groups, but the response was reduced in P rabbits. Mesenteric and renal conductances did not change in either group before the blood pressure fall. During the pressure fall, terminal aortic conductance increased (P < 0.05) only in NP rabbits. Mesenteric conductance increased in both groups. In summary, rabbits in late gestation are less able to maintain arterial pressure during hemorrhage, at least in part because of reduced vasoconstriction in tissues perfused by the terminal aorta.


Asunto(s)
Presión Sanguínea , Hemorragia/fisiopatología , Preñez , Vasodilatación , Animales , Barorreflejo , Femenino , Embarazo , Conejos , Flujo Sanguíneo Regional
18.
Am J Physiol ; 275(4): R1082-90, 1998 10.
Artículo en Inglés | MEDLINE | ID: mdl-9756537

RESUMEN

This study tests the hypothesis that conscious rabbits late in pregnancy (P), but not at midgestation (MP), are less able to maintain arterial pressure during hemorrhage. Blood volume (BV) was elevated (P < 0.05) by an average of 13 +/- 4 (MP) and 35 +/- 3% (P). Rabbits were bled in both the nonpregnant (NP) and P state at 2% of the initial BV per minute. The hemorrhage was stopped after arterial pressure decreased. In NP rabbits, arterial pressure was well maintained near control pressures of 70 +/- 2 mmHg until 38 +/- 2% of the initial BV was removed and then rapidly fell to reach a nadir at 35 +/- 2 mmHg. In contrast, in P rabbits, basal arterial pressure was lower (61 +/- 2 mmHg; P < 0.05) and gradually decreased to below control after <25% of the initial BV was removed. Moreover, the rapid hypotensive phase was triggered with a lower percent BV removal (33 +/- 2%; P < 0.05). Basal heart rate was higher during P (149 +/- 5 vs. 189 +/- 9 beats/min; P < 0.05), and reflex increases were delayed. The slope of the relationship between arterial pressure and vasopressin was not modified during P, although the line was shifted to a lower pressure (P < 0.05). Larger increases in plasma renin activity and ANG II concentration were produced during hemorrhage in P rabbits. In contrast, no differences in the changes in arterial pressure, heart rate, and vasopressin were found between NP and MP rabbits during hemorrhage, although increases in renin and ANG II were greater at MP (P < 0.05). In summary, although P conscious rabbits are less able to maintain blood pressure during hemorrhage, this change is not evident at MP. These data suggest that the factors that mediate the P-induced alterations in arterial pressure regulation are not operative until late in gestation.


Asunto(s)
Angiotensina II/sangre , Hemodinámica/fisiología , Hemorragia/fisiopatología , Complicaciones del Embarazo/fisiopatología , Vasopresinas/metabolismo , Animales , Barorreflejo , Presión Sanguínea , Volumen Sanguíneo , Femenino , Frecuencia Cardíaca , Hematócrito , Embarazo , Conejos , Renina/sangre , Sistema Renina-Angiotensina , Factores de Tiempo , Vasopresinas/sangre
19.
J Biol Chem ; 273(35): 22595-605, 1998 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-9712888

RESUMEN

The transcriptionally active fragment of the yeast RNA polymerase II transcription elongation factor, TFIIS, comprises a three-helix bundle and a zinc ribbon motif joined by a linker region. We have probed the function of this fragment of TFIIS using structure-guided mutagenesis. The helix bundle domain binds RNA polymerase II with the same affinity as does the full-length TFIIS, and this interaction is mediated by a basic patch on the outer face of the third helix. TFIIS mutants that were unable to bind RNA polymerase II were inactive for transcription activity, confirming the central role of polymerase binding in the TFIIS mechanism of action. The linker and zinc ribbon regions play roles in promoting cleavage of the nascent transcript and read-through past the block to elongation. Mutation of three aromatic residues in the zinc ribbon domain (Phe269, Phe296, and Phe308) impaired both transcript cleavage and read-through. Mutations introduced in the linker region between residues 240 and 245 and between 250 and 255 also severely impaired both transcript cleavage and read-through activities. Our analysis suggests that the linker region of TFIIS probably adopts a critical structure in the context of the elongation complex.


Asunto(s)
ARN Polimerasa II/metabolismo , Saccharomyces cerevisiae/metabolismo , Factores Generales de Transcripción , Factores de Transcripción/metabolismo , Factores de Elongación Transcripcional , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Unión Proteica , ARN Mensajero/metabolismo , Relación Estructura-Actividad , Factores de Transcripción/química , Factores de Transcripción/genética , Zinc/química
20.
Am J Physiol ; 273(3 Pt 2): R960-6, 1997 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9321874

RESUMEN

Two studies were performed to determine whether the attenuation of baroreflex control of heart rate during late pregnancy in conscious rabbits is due to changes in parasympathetic (Para) or sympathetic (Sym) control of the heart. In the first, baroreflex relationships between arterial pressure and heart rate were generated before and after treatment with propranolol (Pro) to block Sym or with methscopolamine (Meth) to block Para. Each rabbit was studied in both the pregnant and nonpregnant state. Pregnancy decreased maximum baroreflex gain from 14.9 +/- 4.0 to 4.8 +/- 0.9 beats.min-1.mmHg-1 (P < 0.01) and decreased heart rate range from 177 +/- 6 to 143 +/- 10 beats/min (P < 0.01), primarily by increasing minimum heart rate (114 +/- 6 to 134 +/- 8 beats/min; P < 0.01). The difference between pregnant and nonpregnant rabbits in baroreflex gain was not altered by Meth but was abolished by Pro, suggesting that it is due to decreased Sym control of the heart. The elevated minimum heart rate of pregnancy persisted after Pro, but was abolished by Meth, suggesting that it is mediated by decreased Para control of the heart. In the second study, isolated buffer-perfused hearts from pregnant and nonpregnant rabbits were treated with increasing doses of isoproterenol (0.3-300 mM) or acetylcholine (0.3-10,000 microM), and the heart rate responses were determined. Hearts from pregnant rabbits were more sensitive to isoproterenol (P < 0.05), but less responsive to acetylcholine (P < 0.05). In conclusion, pregnancy-induced decreases in cardiac reflex gain and range appear to be mediated by alterations in Sym and Para, respectively. The change in Sym occurs proximal to the heart, whereas the decreased contribution of Para may be due, at least in part, to decreased sensitivity of the heart to acetylcholine.


Asunto(s)
Barorreflejo/fisiología , Frecuencia Cardíaca , Sistema Nervioso Parasimpático/fisiología , Preñez/fisiología , Sistema Nervioso Simpático/fisiología , Acetilcolina/farmacología , Animales , Aorta Abdominal/fisiología , Barorreflejo/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Isoproterenol/farmacología , N-Metilescopolamina , Sistema Nervioso Parasimpático/efectos de los fármacos , Embarazo , Propranolol/farmacología , Conejos , Valores de Referencia , Derivados de Escopolamina/farmacología , Sistema Nervioso Simpático/efectos de los fármacos , Vena Cava Inferior/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA